IsoRay ships first set of Cesium-131 brachytherapy seeds to Canada

IsoRay, Inc. (AMEX: ISR) announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).

“Inter V Medical, our distributor, brings to IsoRay Medical a team of nine dedicated sales professionals strategically placed across Canada with exclusive rights to sell Cesium-131 brachytherapy seeds. Inter V Medical has been bringing new medical technologies, including brachytherapy and related products, to the Canadian market for nearly twenty years.”

IsoRay Medical, in conjunction with its Canadian distribution partner, Inter V Medical, looks forward to expanding the application of Cesium-131 for other cancer treatment areas of the body. IsoRay is seeking additional clinical evidence to allow Health Canada to approve expanded indications for use of Cesium-131 for other malignant disease locations. The goal is to obtain approvals for a wide variety of malignant disease sites (as has already been obtained in the United States).

Dwight Babcock, Chairman and CEO, stated, “We are very excited to take this first step in gathering clinical data to support the expanded use of Cesium-131 in Canada. We have experienced successful treatments of numerous cancers here in the US, such as lung, head and neck, and colon cancers, and look forward to bringing this technology to physicians in Canada to use in treating their patients. We are working closely with our distribution partner Inter V Medical to expedite the penetration of the Canadian market.”

Babcock continued, “Inter V Medical, our distributor, brings to IsoRay Medical a team of nine dedicated sales professionals strategically placed across Canada with exclusive rights to sell Cesium-131 brachytherapy seeds. Inter V Medical has been bringing new medical technologies, including brachytherapy and related products, to the Canadian market for nearly twenty years.”

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What is the difference in risk of early prostate cancer death between men at higher vs lower genetic risk?